GSK PLC Statement: Zantac (ranitidine) litigation (1677U)
24 March 2023 - 08:59PM
UK Regulatory
TIDMGSK
RNS Number : 1677U
GSK PLC
24 March 2023
Issued: 24 March 2023, London UK
Statement: Zantac (ranitidine) litigation
In response to yesterday's Sargon ruling by the California state
court in respect of the Goetz case, GSK plc (LSE/NYSE: GSK) today
issued the following statement:
GSK respectfully disagrees with this ruling by the California
state court. Following the 13 epidemiological studies conducted
looking at human data regarding the use of ranitidine, the
scientific consensus is that there is no consistent or reliable
evidence that ranitidine increases the risk of any cancer.
The litigation is still at an early stage and yesterday's
decision relates only to the question of whether the plaintiff's
experts can testify at trial in the Goetz case. It does not mean
that the Court agrees with plaintiff's experts' scientific
conclusions or their litigation-driven science. GSK will press
additional defences and the plaintiff still needs to prove his case
at trial.
This ruling does not affect other state cases or the December
2022 Daubert ruling made in the federal Multi-District
Litigation.
About GSK
GSK is a global biopharma company with a purpose to unite
science, technology, and talent to get ahead of disease together.
Find out more at gsk.com/company
GSK enquiries
Media: Tim Foley +44 (0) 20 8047 (London)
5502
Dan Smith +44 (0) 20 8047 (London)
5502
Kathleen Quinn +1 202 603 5003 (Washington DC)
Lyndsay Meyer +1 202 302 4595 (Washington DC)
Investor Relations: Nick Stone +44 (0) 7717 618834 (London)
James Dodwell +44 (0) 20 8047 (London)
2406
Mick Readey +44 (0) 7990 339653 (London)
Josh Williams +44 (0) 7385 415719 (London)
Camilla Campbell +44 (0) 7803 050238 (London)
Steph Mountifield +44 (0) 7796 707505 (London)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Frannie DeFranco +1 215 751 4855 (Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors" in the company's Annual Report on Form 20-F for
2022, GSK's Q4 Results for 2022 and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUMAWUPWUBC
(END) Dow Jones Newswires
March 24, 2023 05:59 ET (09:59 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024